[1]沈明虹.上皮性卵巢癌HMGB3表达及预后价值的生物信息学分析[J].福建医药杂志,2023,45(06):1-3.
　SHEN Minghong.Analysis of HMGB3 expression and prognostic value in epithelial ovarian cancer based on bioinformatics[J].FUJIAN MEDICAL JOURNAL,2023,45(06):1-3.
点击复制

上皮性卵巢癌HMGB3表达及预后价值的生物信息学分析()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期数:
2023年06期
页码:
1-3
栏目:
临床研究
出版日期:
2023-12-15

文章信息/Info

Title:
Analysis of HMGB3 expression and prognostic value in epithelial ovarian cancer based on bioinformatics
文章编号:
1002-2600(2023)06-0001-03
作者:
沈明虹
福建省立医院妇科(福州 350001)
Author(s):
SHEN Minghong
Department of Gynecology, Fujian Provincial Hospital, Fuzhou, Fujian 350001, China
关键词:
上皮性卵巢癌;  高迁移率族蛋白B3;  生物信息学;  预后
Keywords:
epithelial ovarian cancer;  high mobility group box B3;  bioinformatics;  prognosis
分类号:
R737.31
文献标志码:
A
摘要:
目的 探讨高迁移率族蛋白B3(HMGB3)在上皮性卵巢癌(EOC)中的表达及其与EOC患者预后的关系。方法 应用GEPIA2、UALCAN及TIMER 2.0数据库分析HMGB3在EOC组织中的表达水平及其与预后的相关性; 通过UALCAN分析HMGB3可能参与调控的信号通路; 利用TIMER 2.0分析HMGB3表达对肿瘤微环境中免疫细胞浸润的影响,分析HMGB3基因与PARP1、PARP2基因表达的相关性。结果 1)EOC组织中HMGB3的表达水平显著上调(P<0.05); 2)HMGB3高表达EOC患者的无病生存率、总生存率均显著优于HMGB3低表达患者(P均<0.05); 3)HMGB3高表达与CD4+T细胞、CD8+T细胞的高丰度相关(r=0.191,0.153,P均<0.05); 4)HMGB3基因与PARP1、PARP2基因表达呈正相关(r=0.308,0.398,P均<0.001)。结论 HMGB3在EOC组织中显著上调,其高表达预示EOC患者预后良好,并与PARP1、PARP2基因表达相关,可作为EOC预后相关的潜在生物标志物。
Abstract:
Objective To explore the expression of high mobility group box B3(HMGB3)in epithelial ovarian cancer(EOC)and its relationship with the prognosis of EOC patients. Methods GEPIA2, UALCAN and TIMER 2.0 databases were used to analyze the expression level of HMGB3 in EOC tissues, its correlation with EOC patients prognosis, the signaling pathways that HMGB3 may participate in regulation, the effects of HMGB3 expression on immune cell infiltration in tumor microenvironment, and the correlations between HMGB3 and PARP1/2.Results The expression levels of HMGB3 in EOC tissues were significantly upregulated(P<0.05).Disease-free survival and overall survival of EOC patients with high expression levels of HMGB3 were significantly higher than those with low expression levels of HMGB3(P<0.05).High expression levels of HMGB3 were correlated with the high abundance of CD4+T cells and CD8+T cells [correlation coefficients(r)were 0.191 and 0.153, respectively, both P<0.05].HMGB3 was positively correlated with the PARP1 and PARP2 genes(r=0.308, P<0.001; r=0.398, P<0.001).Conclusion HMGB3 is significantly upregulated in EOC tissues.High expression levels of HMGB3 predicts a good prognosis in EOC patients and is associated with the expression levels of PARP1 and PARP2 genes, which can serve as a potential biomarker for EOC patients.

参考文献/References:

[1] Odunsi K.Immunotherapy in ovarian cancer[J].Ann Oncol,2017, 28(suppl_8):viii1-viii7.
[2] Fang J,Ge X,Xu W, et al.Bioinformatics analysis of the prognosis and biological significance of HMGB1, HMGB2, and HMGB3 in gastric cancer[J].J Cell Physiol,2020, 235(4):3438-3446.
[3] Wen B,Wei Y T,Zhao K.The role of high mobility group protein B3(HMGB3)in tumor proliferation and drug resistance[J].Mol Cell Biochem, 2021, 476(4):1729-1739.
[4] Xie X,Pan J,Han X, et al.Downregulation of microRNA-532-5p promotes the proliferation and invasion of bladder cancer cells through promotion of HMGB3/Wnt/β-catenin signaling[J].Chem Biol Interact, 2019, 300:73-81.
[5] Song N, Wang B,Feng G,et al.Knockdown of high mobility group box 3 impairs cell viability and colony formation but increases apoptosis in A549 human non-small cell lung cancer cells[J].Oncol Lett,2019, 17(3):2937-2945.
[6] Mukherjee A,Huynh V,Gaines K,et al.Targeting the high-mobility group box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin[J].Cancer Res, 2019,79(13):3185-3191.
[7] Zhou X,Zhang Q,Liang G,et al.Overexpression of HMGB3 and its prognostic value in breast cancer[J].Front Oncol,2022, 12:1048921.
[8] Gong W,Guo Y,Yuan H,et al.HMGB3 is a potential therapeutic target by affecting the migration and proliferation of colorectal cancer[J].Front Cell Dev Biol, 2022, 10:891482.
[9] Zheng X,Wang X,He Y, et al.Systematic analysis of expression profiles of HMGB family members for prognostic application in non-small cell lung cancer[J].Front Mol Biosci, 2022,9:844618.
[10] Li M,Cai Y,Zhao H,et al.Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients[J].Tumour Biol, 2015, 36(6):4785-4792.
[11] Shimizu S,Hiratsuka H,Koike K, et al.Tumor-infiltrating CD8+ T-cell density is an independent prognostic marker for oral squamous cell carcinoma[J].Cancer Med, 2019,8(1):80-93.
[12] Oda K,Kato K,Nakamura M, et al.Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infifiltrating lymphocytes in lung cancer patients treated with pembrolizumab[J].Lung Cancer, 2018,118:171-172.
[13] Batista F D,Harwood N E.The who, how and where of antigen presentation to b cells[J].Nat Rev Immunol, 2009, 9(1):15-27.
[14] Revythis A,Limbu A,Mikropoulos C, et al.Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer[J].Int J Environ Res Public Health, 2022, 19(14):8577.
[15] Zuo W W,Zhao C F,Li Y, et al.High expression of PARP1 in tumor and stroma cells predicts different prognosis and platinum resistance in patients with advanced epithelial ovarian cancer[J].Front Oncol, 2022,12: 931445.
[16] Revythis A,Limbu A,Mikropoulos C, et al.Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer[J].Int J Environ Res Public Health, 2022, 19(14):8577.
[17] Ma H,Qi G,Han F, et al.HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer[J].Cell Death Dis, 2022, 13(3):263.

相似文献/References:

[1]刘小梅,庄良武,章斌斌.术前中性粒细胞/淋巴细胞比值对上皮性卵巢癌患者术后生存率的影响[J].福建医药杂志,2021,43(04):7.
　LIU Xiaomei,ZHUANG Liangwu,ZHANG Binbin.Preoperative neutrophil/lymphocyte ratio predicts postoperative survival rate in patients with epithelial ovarian cancer[J].FUJIAN MEDICAL JOURNAL,2021,43(06):7.

备注/Memo

备注/Memo:
基金项目:福建省卫健委中青年骨干人才培养项目(2021GGA008)
更新日期/Last Update: 2023-12-15